Published in Schizophr Bull on January 01, 1990
Regional and cellular fractionation of working memory. Proc Natl Acad Sci U S A (1996) 2.85
Schizophrenia and cognitive dysmetria: a positron-emission tomography study of dysfunctional prefrontal-thalamic-cerebellar circuitry. Proc Natl Acad Sci U S A (1996) 2.40
The impact of NMDA receptor hypofunction on GABAergic neurons in the pathophysiology of schizophrenia. Schizophr Res (2015) 2.14
Toward a neurobiology of delusions. Prog Neurobiol (2010) 1.70
Are anticorrelated networks in the brain relevant to schizophrenia? Schizophr Bull (2007) 1.65
Voxel-based morphometry of patients with schizophrenia or bipolar I disorder: a matched control study. Psychiatry Res (2011) 1.65
Characterizing thalamo-cortical disturbances in schizophrenia and bipolar illness. Cereb Cortex (2013) 1.40
Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view. Antioxid Redox Signal (2011) 1.32
Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment. Lancet Psychiatry (2015) 1.29
Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia. Schizophr Bull (2007) 1.21
Testing models of thalamic dysfunction in schizophrenia using neuroimaging. J Neural Transm (Vienna) (2005) 1.02
A broken filter: prefrontal functional connectivity abnormalities in schizophrenia during working memory interference. Schizophr Res (2012) 1.01
Connectivity, pharmacology, and computation: toward a mechanistic understanding of neural system dysfunction in schizophrenia. Front Psychiatry (2013) 1.00
Animal models of schizophrenia: a critical review. J Psychiatry Neurosci (2001) 0.91
Neurofunctional model of large-scale correlates of selective attention governed by stimulus-novelty. Cogn Neurodyn (2011) 0.91
Does maternal body mass index during pregnancy influence risk of schizophrenia in the adult offspring? Obes Rev (2011) 0.90
D-serine as a gliotransmitter and its roles in brain development and disease. Front Cell Neurosci (2013) 0.89
Is there a role for immune-to-brain communication in schizophrenia? Psychopharmacology (Berl) (2015) 0.87
Hypermetabolic pattern in frontal cortex and other brain regions in unmedicated schizophrenia patients. Results from a FDG-PET study. Eur Arch Psychiatry Clin Neurosci (2005) 0.87
Glutamate, N-acetyl aspartate and psychotic symptoms in chronic ketamine users. Psychopharmacology (Berl) (2013) 0.87
Sex-dependent antipsychotic capacity of 17β-estradiol in the latent inhibition model: a typical antipsychotic drug in both sexes, atypical antipsychotic drug in males. Neuropsychopharmacology (2010) 0.84
Deficits in probabilistic classification learning and liability for schizophrenia. Psychiatry Res (2012) 0.84
Concurrent functional magnetic resonance imaging and electroencephalography assessment of sensory gating in schizophrenia. Hum Brain Mapp (2013) 0.84
The dopamine hypothesis of schizophrenia: limbic interactions with serotonin and norepinephrine. Psychopharmacology (Berl) (1993) 0.84
Ketamine versus propofol for strabismus surgery in children. Clin Ophthalmol (2010) 0.84
Clinical correlates of thalamus volume deficits in anti-psychotic-naïve schizophrenia patients: A 3-Tesla MRI study. Indian J Psychiatry (2010) 0.82
Microstructural thalamic changes in schizophrenia: a combined anatomic and diffusion weighted magnetic resonance imaging study. J Psychiatry Neurosci (2008) 0.81
Partial genetic deletion of neuregulin 1 and adolescent stress interact to alter NMDA receptor binding in the medial prefrontal cortex. Front Behav Neurosci (2014) 0.80
Brain mechanisms of hallucinogens and entactogens. Dialogues Clin Neurosci (2001) 0.79
Pupillometric measures of attentional allocation to target and mask processing on the backward masking task in schizophrenia. Psychophysiology (2009) 0.79
Treadmill exercise inhibits hippocampal apoptosis through enhancing N-methyl-D-aspartate receptor expression in the MK-801-induced schizophrenic mice. J Exerc Rehabil (2014) 0.78
Activity of D-amino acid oxidase is widespread in the human central nervous system. Front Synaptic Neurosci (2014) 0.78
Functional hierarchy underlies preferential connectivity disturbances in schizophrenia. Proc Natl Acad Sci U S A (2015) 0.78
The role of D-serine as co-agonist of NMDA receptors in the nucleus accumbens: relevance to cocaine addiction. Front Synaptic Neurosci (2014) 0.78
Acute effects of the designer drugs benzylpiperazine (BZP) and trifluoromethylphenylpiperazine (TFMPP) using functional magnetic resonance imaging (fMRI) and the Stroop task--a pilot study. Psychopharmacology (Berl) (2015) 0.77
Current hypotheses on sigma receptors and their physiological role: possible implications in psychiatry. J Psychiatry Neurosci (1993) 0.77
Inferring reward prediction errors in patients with schizophrenia: a dynamic reward task for reinforcement learning. Front Psychol (2014) 0.77
A conceptual and practical guide to the behavioural evaluation of animal models of the symptomatology and therapy of schizophrenia. Cell Tissue Res (2013) 0.76
Striatal dopamine, reward, and decision making in schizophrenia. Dialogues Clin Neurosci (2016) 0.76
Effect of ketamine pretreatment for anaesthesia in patients undergoing percutaneous transluminal balloon angioplasty with continuous remifentanil infusion. Korean J Anesthesiol (2011) 0.75
Cross-sectional Study of Glutamate in the Anterior Cingulate and Hippocampus in Schizophrenia. Schizophr Bull (2015) 0.75
Glutamatergic ionotropic blockade within accumbens disrupts working memory and might alter the endocytic machinery in rat accumbens and prefrontal cortex. J Neural Transm (Vienna) (2007) 0.75
A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. N Engl J Med (1995) 4.71
The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. N Engl J Med (1997) 3.49
A prospective randomised trial of internal fixation versus arthroplasty for displaced fractures of the neck of the femur. Functional outcome for 450 patients at two years. J Bone Joint Surg Br (2002) 3.40
Effect of antidepressant drugs on the depletion of intraneuronal brain 5-hydroxytryptamine stores caused by 4-methyl-alpha-ethyl-meta-tyramine. Eur J Pharmacol (1969) 2.61
Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes (1999) 2.36
Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. J Thromb Haemost (2006) 2.32
Effects of some antidepressant drugs on the depletion of intraneuronal brain catecholamine stores caused by 4,alpha-dimethyl-meta-tyramine. Eur J Pharmacol (1969) 2.26
The dopamine D3-receptor: a postsynaptic receptor inhibitory on rat locomotor activity. J Neural Transm Gen Sect (1993) 2.20
The effects of probiotics on barrier function and mucosal pouch microbiota during maintenance treatment for severe pouchitis in patients with ulcerative colitis. Aliment Pharmacol Ther (2013) 2.01
Interactions between glutamatergic and monoaminergic systems within the basal ganglia--implications for schizophrenia and Parkinson's disease. Trends Neurosci (1990) 1.91
Modification of sympathetic function. Pharmacological depletion of catecholamine stores. Pharmacol Rev (1966) 1.56
Movement patterns of the C-stem femoral component: an RSA study of 33 primary total hip arthroplasties followed for two years. J Bone Joint Surg Br (2005) 1.53
Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia. Am J Med (1993) 1.50
Biochemical and histochemical studies on the effects of imipramine-like drugs and (+)-amphetamine on central and peripheral catecholamine neurons. Acta Physiol Scand (1967) 1.49
Continuous distal migration and internal rotation of the C-stem prosthesis without any adverse clinical effects: an RSA study of 33 primary total hip arthroplasties followed for up to ten years. Bone Joint J (2014) 1.45
Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia. Biol Psychiatry (2000) 1.43
Insect immunity. The primary structure of the antibacterial protein attacin F and its relation to two native attacins from Hyalophora cecropia. EMBO J (1984) 1.35
Oral L-dopa treatment of parkinsonism. Acta Med Scand (1970) 1.35
Central and peripheral monoaminergic membrane-pump blockade by some addictive analgesics and antihistamines. J Pharm Pharmacol (1969) 1.34
Ammonia synthesis from first-principles calculations. Science (2005) 1.33
Dependence of 5-HT and catecholamine synthesis on concentrations of precursor amino-acids in rat brain. Naunyn Schmiedebergs Arch Pharmacol (1978) 1.31
Long-term follow-up of replacement compared with internal fixation for displaced femoral neck fractures: results at ten years in a randomised study of 450 patients. J Bone Joint Surg Br (2010) 1.30
Histochemical amd biochemical effects of diethyldithiocarbamate on tissue catecholamines. J Pharm Pharmacol (1966) 1.29
Blood pressure course in patients with acute stroke and matched controls. Stroke (1986) 1.28
Perspectives on the discovery of central monoaminergic neurotransmission. Annu Rev Neurosci (1987) 1.27
The effect of imipramine on central 5-hydroxytryptamine neurons. J Pharm Pharmacol (1968) 1.21
The antibacterial effect of attacins from the silk moth Hyalophora cecropia is directed against the outer membrane of Escherichia coli. EMBO J (1984) 1.19
Simultaneous measurement of tyrosine and tryptophan hydroxylase activities in brain in vivo using an inhibitor of the aromatic amino acid decarboxylase. Naunyn Schmiedebergs Arch Pharmacol (1972) 1.19
Influence of age and time interval between death and autopsy on dopamine and 3-methoxytyramine levels in human basal ganglia. J Neural Transm (1976) 1.18
Bone mass in primary coxarthrosis. Acta Orthop Scand (1979) 1.18
Exposure to toluene: uptake, distribution and elimination in man. Scand J Work Environ Health (1982) 1.17
Clinical aspects of osseointegration in joint replacement. A histological study of titanium implants. J Bone Joint Surg Br (1988) 1.12
Does tranexamic acid reduce blood loss in knee arthroplasty? Am J Knee Surg (1995) 1.12
Adrenergic mechanisms. Annu Rev Pharmacol (1969) 1.11
The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice. J Neural Transm (1989) 1.10
Schizophrenia: from dopamine to glutamate and back. Curr Med Chem (2004) 1.09
Molecular genetic analysis of long QT syndrome in Norway indicating a high prevalence of heterozygous mutation carriers. Scand J Clin Lab Invest (2008) 1.09
The effect of taurine on motor behaviour, body temperature and monoamine metabolism in rat brain. Naunyn Schmiedebergs Arch Pharmacol (1978) 1.08
Antipsychotic drugs, neurotransmitters, and schizophrenia. Am J Psychiatry (1978) 1.07
Seasonal and circadian monoamine variations in human brains examined post mortem. Acta Psychiatr Scand Suppl (1980) 1.07
Mannose-resistant haemagglutination by Campylobacter pylori. Scand J Infect Dis (1988) 1.05
Exposure to toluene: concentration in subcutaneous adipose tissue. Scand J Work Environ Health (1982) 1.04
8-Hydroxy-2-(di-n-propylamino)tetralin, a new centrally acting 5-hydroxytryptamine receptor agonist. J Med Chem (1981) 1.04
The three ZNT8 autoantibody variants together improve the diagnostic sensitivity of childhood and adolescent type 1 diabetes. Autoimmunity (2011) 1.04
Gloverin, an antibacterial protein from the immune hemolymph of Hyalophora pupae. Eur J Biochem (1997) 1.04
The effect of hypoxia on monoamine synthesis, levels and metabolism in rat brain. J Neurochem (1973) 1.03
Does dopamine play a role in schizophrenia? Psychol Med (1977) 1.02
Vibration white finger: a follow up study. Br J Ind Med (1987) 1.02
Evidence for a receptor-mediated feedback control of striatal tyrosine hydroxylase activity. J Pharm Pharmacol (1972) 1.02
Aseptic loosening of hip prostheses. A histologic and enzyme histochemical study. Clin Orthop Relat Res (1983) 1.01
Temporal trends of HLA genotype frequencies of type 1 diabetes patients in Sweden from 1986 to 2005 suggest altered risk. Acta Diabetol (2008) 1.01
Antipsychotic properties of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine(preclamol) in schizophrenia. Biol Psychiatry (1998) 1.01
Effects of antidepressant agents on the synthesis of brain monoamines. J Neural Transm (1978) 1.00
Behavioral and neurochemical data suggest functional differences between dopamine D2 and D3 receptors. Eur J Pharmacol (1994) 1.00
Social function after cervical hip fracture. A comparison of hook-pins and total hip replacement in 47 patients. Acta Orthop Scand (1996) 1.00
Does dopamine have a role in schizophrenia? Biol Psychiatry (1978) 1.00
Effects of a new type of 5-HT receptor agonist on male rat sexual behavior. Pharmacol Biochem Behav (1981) 0.99
Very high blood pressure in acute stroke. J Intern Med (1990) 0.99
C-peptide in the classification of diabetes in children and adolescents. Pediatr Diabetes (2011) 0.98
The apparent autoxidation rate of catechols in dopamine-rich regions of human brains increases with the degree of depigmentation of substantia nigra. J Neural Transm Park Dis Dement Sect (1989) 0.98
In vivo effects of the Ca2+-antagonist nimodipine on dopamine metabolism in mouse brain. J Neural Transm (1986) 0.98
Biochemical and pharmacological aspects of Parkinsonism. Acta Neurol Scand Suppl (1972) 0.98
Detection of 5-S-cysteinyldopamine in human brain. J Neural Transm (1985) 0.98
Partial dopamine agonists and dopaminergic stabilizers, in the treatment of psychosis. Curr Drug Targets CNS Neurol Disord (2002) 0.97
Innate immune responses in Lyme borreliosis: enhanced tumour necrosis factor-alpha and interleukin-12 in asymptomatic individuals in response to live spirochetes. Clin Exp Immunol (2005) 0.97
Effects of the amphetamine group on intraneuronal brain amines in vivo and in vitro. J Pharm Pharmacol (1965) 0.97
Brain tryptophan hydroxylation: dependence on arterial oxygen tension. Science (1973) 0.97
Biogenic amines in human brain in normal aging, senile dementia, and chronic alcoholism. Adv Biochem Psychopharmacol (1980) 0.97
The cost-effectiveness of risedronate in the treatment of osteoporosis: an international perspective. Osteoporos Int (2006) 0.96
Inhibition of ethanol-induced excitation in mice and rats by -methyl-p-tyrosine. Psychopharmacologia (1972) 0.96
Children developing type 1 diabetes before 6 years of age have increased linear growth independent of HLA genotypes. Diabetologia (2008) 0.96
Structural specificity for inhibition of [14C]-5-hydroxytryptamine uptake by cerebral slices. J Pharm Pharmacol (1970) 0.95
3-PPP, a new centrally acting DA-receptor agonist with selectivity for autoreceptors. Life Sci (1981) 0.95
Occurrence and distribution of 5-S-cysteinyl derivatives of dopamine, dopa and dopac in the brains of eight mammalian species. Neuropharmacology (1986) 0.95
3-Phenylpiperidines. Central dopamine-autoreceptor stimulating activity. J Med Chem (1981) 0.94
Exposure to methylene chloride. I Its concentration in alveolar air and blood during rest and exercise and its metabolism. Scand J Work Environ Health (1975) 0.93
Effect of ethanol on the hydroxylation of tyrosine and tryptophan in rat brain in vivo. J Pharm Pharmacol (1973) 0.93
Recent studies on the mode of action of antidepressive drugs. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol (1967) 0.92
Central dopamine receptor agonist and antagonist actions of the enantiomers of 3-PPP. Psychopharmacology (Berl) (1983) 0.92
Is pindolol a mixed agonist-antagonist at central serotonin (5-HT) receptors? Eur J Pharmacol (1986) 0.92
The accumulation of [3H]noradrenaline in the adrenergic nerve fibres of reserpine-treated mice. J Pharm Pharmacol (1967) 0.92
Differential effects of the N-methyl-d-aspartate receptor antagonist MK-801 on different stages of object recognition memory in mice. Neuroscience (2007) 0.92
Previous exposure to measles, mumps, and rubella--but not vaccination during adolescence--correlates to the prevalence of pancreatic and thyroid autoantibodies. Pediatrics (1999) 0.92
The influence of nerve-impulse flow on the synthesis and metabolism of 5-hydroxytryptamine in the central nervous system. Biochem Soc Symp (1972) 0.91
Biochemical changes in dementia disorders of Alzheimer type (AD/SDAT). Neurobiol Aging (1983) 0.91
[Blood loss in Charnley's total hip replacement]. Lakartidningen (1977) 0.91
Transmission of human T-cell lymphotrophic virus type 1 by a deep-frozen bone allograft. Acta Orthop Scand (1997) 0.91
Locomotor inhibition by the D3 ligand R-(+)-7-OH-DPAT is independent of changes in dopamine release. J Neural Transm Gen Sect (1994) 0.90
Triple specificity of ZnT8 autoantibodies in relation to HLA and other islet autoantibodies in childhood and adolescent type 1 diabetes. Pediatr Diabetes (2012) 0.90
A regional study of sex differences in rat brain serotonin. Prog Neuropsychopharmacol Biol Psychiatry (1988) 0.90
Suppression of ethanol-induced locomotor stimulation by GABA-like drugs. Naunyn Schmiedebergs Arch Pharmacol (1976) 0.89
A method for the determination of 3,4-dihydroxyphenylalanine (DOPA) in brain. Naunyn Schmiedebergs Arch Pharmacol (1972) 0.89
Potentiation of the antidepressant action of clomipramine by tryptophan. Arch Gen Psychiatry (1976) 0.89
Buspirone: effects on central monoaminergic transmission--possible relevance to animal experimental and clinical findings. Eur J Pharmacol (1982) 0.89
Distribution of dopamine in the rat cerebral cortex. J Neural Transm (1976) 0.89
In-vivo measurements of tryptophan and tyrosine hydroxylase activities in mouse brain. J Neural Transm (1973) 0.88
Total hip replacement with a zirconium oxide ceramic femoral head: a randomised roentgen stereophotogrammetric study. J Bone Joint Surg Br (2005) 0.88
A marked rise in 5-S-cysteinyl-dopamine levels in guinea-pig striatum following reserpine treatment. J Neural Transm (1989) 0.88
Cost of depression: effect of adherence and treatment response. Eur Psychiatry (2006) 0.87
MK-801-induced hyperlocomotion: differential effects of M100907, SDZ PSD 958 and raclopride. Eur J Pharmacol (1997) 0.87